189 related articles for article (PubMed ID: 15710953)
1. Summaries for patients. Combination therapy for chronic hepatitis B.
Ann Intern Med; 2005 Feb; 142(4):I30. PubMed ID: 15710953
[No Abstract] [Full Text] [Related]
2. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.
Chan HL; Leung NW; Hui AY; Wong VW; Liew CT; Chim AM; Chan FK; Hung LC; Lee YT; Tam JS; Lam CW; Sung JJ
Ann Intern Med; 2005 Feb; 142(4):240-50. PubMed ID: 15710957
[TBL] [Abstract][Full Text] [Related]
3. Does the addition of lamivudine to peginterferon alpha-2a sustain response rates in HBeAg-negative hepatitis B?
Cooksley G
Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):12-3. PubMed ID: 16265091
[No Abstract] [Full Text] [Related]
4. [Interferon therapy for chronic hepatitis B].
Tang WL; Xie Q
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):726-9. PubMed ID: 19874685
[No Abstract] [Full Text] [Related]
5. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
7. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
Lampertico P; Viganò M; Di Costanzo GG; Sagnelli E; Fasano M; Di Marco V; Boninsegna S; Farci P; Fargion S; Giuberti T; Iannacone C; Regep L; Massetto B; Facchetti F; Colombo M;
Gut; 2013 Feb; 62(2):290-8. PubMed ID: 22859496
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon and lamivudine for hepatitis B.
Assy NN; Hussein O
N Engl J Med; 2004 Dec; 351(27):2879; author reply 2879. PubMed ID: 15625344
[No Abstract] [Full Text] [Related]
9. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
Schiefke I; Klecker C; Maier M; Oesen U; Etzrodt G; Tannapfel A; Liebert UG; Berr F
Liver Int; 2004 Apr; 24(2):98-104. PubMed ID: 15078472
[TBL] [Abstract][Full Text] [Related]
10. Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
Song K; Rajvanshi P
N Engl J Med; 2005 Oct; 353(15):1630-1; author reply 1630-1. PubMed ID: 16221792
[No Abstract] [Full Text] [Related]
11. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study.
Mutimer D; Naoumov N; Honkoop P; Marinos G; Ahmed M; de Man R; McPhillips P; Johnson M; Williams R; Elias E; Schalm S
J Hepatol; 1998 Jun; 28(6):923-9. PubMed ID: 9672165
[TBL] [Abstract][Full Text] [Related]
12. A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B.
Manesis EK; Papatheodoridis GV; Hadziyannis SJ
Aliment Pharmacol Ther; 2006 Jan; 23(1):99-106. PubMed ID: 16393286
[TBL] [Abstract][Full Text] [Related]
13. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hepatitis B with interferon and combination therapy.
Cooksley WG
Clin Liver Dis; 2004 May; 8(2):353-70. PubMed ID: 15481344
[TBL] [Abstract][Full Text] [Related]
15. Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation.
Seehofer D; Rayes N; Neuhaus R; Berg T; Müller AR; Bechstein WO; Neuhaus P
Transpl Int; 2000; 13 Suppl 1():S359-62. PubMed ID: 11112032
[TBL] [Abstract][Full Text] [Related]
16. The maze of treatments for hepatitis B.
Lok AS
N Engl J Med; 2005 Jun; 352(26):2743-6. PubMed ID: 15987924
[No Abstract] [Full Text] [Related]
17. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
Ratnam D; Dev A; Nguyen T; Sundararajan V; Harley H; Cheng W; Lee A; Rusli F; Chen R; Bell S; Pianko S; Sievert W
J Gastroenterol Hepatol; 2012 Sep; 27(9):1447-53. PubMed ID: 22168789
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.
Suh DJ; Lee HC; Byun KS; Cho M; Kweon YO; Tak WY; Chon CY; Koh KC; Lee YS
Antivir Ther; 2013; 18(6):765-73. PubMed ID: 23900457
[TBL] [Abstract][Full Text] [Related]
19. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
Bonino F; Marcellin P; Lau GK; Hadziyannis S; Jin R; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Brunetto MR; Farci P; Popescu M; McCloud P;
Gut; 2007 May; 56(5):699-705. PubMed ID: 17127704
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
